Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Net Income: 2016-2024

Historic Net Income for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$43.3 million.

  • Mereo BioPharma Group's Net Income rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Net Income is -$43.3 million, which was down 46.79% from -$29.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Net Income ranged from a high of $17.2 million in FY2021 and a low of -$210.1 million during FY2020.
  • Its 3-year average for Net Income is -$38.3 million, with a median of -$42.2 million in 2022.
  • Per our database at Business Quant, Mereo BioPharma Group's Net Income slumped by 372.29% in 2020 and then spiked by 108.16% in 2021.
  • Mereo BioPharma Group's Net Income (Yearly) stood at -$210.1 million in 2020, then skyrocketed by 108.16% to $17.2 million in 2021, then slumped by 346.13% to -$42.2 million in 2022, then spiked by 30.21% to -$29.5 million in 2023, then plummeted by 46.79% to -$43.3 million in 2024.